Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A "smarter" chemotherapy

Current Pharmaceutical Design

Volumn 11, Issue 9, 2005, Pages 1167-1180

  Nagy, A ^a   Schally, A V ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytotoxic conjugates; Doxorubicin; Experimental tumor therapy; Hypothalamic hormones; Mechanism of action; Targeting; Tumoral receptors

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 181; AN 215; ANTINEOPLASTIC AGENT; BOMBESIN; BOMBESIN RECEPTOR; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN; GASTRIN RELEASING PEPTIDE; GONADORELIN; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; PENTETREOTIDE; RC 3095; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BRAIN TUMOR; BREAST CANCER; CANCER GRADING; CANCER INHIBITION; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LETHAL DOSE; LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER;

ANIMALS; BOMBESIN; DRUG DELIVERY SYSTEMS; GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASMS; RECEPTORS, BOMBESIN; RECEPTORS, DRUG; RECEPTORS, LHRH; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 15544371477     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053507594     Document Type: Review

References (108)

1. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999; 141: 1-14.
2. Reubi J-C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev 2003; 24: 389-427.
3. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
4. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Rev Drug Discovery 2003; 2: 999-1017.
5. Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 2003; 1616:1-84.
6. Schally AV. Oncological applications of somatostatin analogs. Cancer Research 1988; 48: 6977-85.
7. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer. Frontiers Neuroendocrinol 2001; 22: 248-91.
8. Nagy A, Schally AV, Halmos G, Armatis P, Cai R-Z, Csernus V, et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative 2-pyrrolinodoxonubicin. Proc Natl Acad Sci USA 1998; 95: 1794-9.
9. Nagy A, Schally AV. Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers. Drugs Fut 2001; 26: 261-70.
10. Dondi D, Limonta P, Moretti RM, Marrelli Montagnani M, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994; 54: 4091-5.
11. Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1989; 86: 1648-51.
12. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993; 53: 5439-46.
13. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996; 93: 7269-73.
14. Nagy A, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapy. Drugs Fut 2002; 27: 359-70.
15. Ben-Yehudah A, Prus D, Lorberboum-Galski H. I.V. Administration of L-GnRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice. Int J Cancer 2001; 92: 263-8.
16. Leuschner C, Enright FM, Gawronska-Kozak B, Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003; 56: 239-49.
17. Nagy A, Armatis P, Cai R-Z, Szepeshazi K, Halmos G, Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1997; 94: 652-6.
18. Kiaris H, Schally AV, Nagy A, Sun B, Armatis P, Szepeshazi K. Targeted Cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. Br J Cancer 1999; 81: 966-71.
19. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer 2000; 88: 652-657.
20. Szepeshazi K, Schally, AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003; 98: 1401-10.
21. Szereday Z, Schally AV, Nagy A, Plonowski A, Bajo AM, Halmos G, et al. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue. AN-215. Br J Cancer 2002; 86: 1322-7.
22. Reubi J-C, Schaer J-C, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and peritumoral vessels. Metabolism: Clinical and Experimental 1996; 8(suppl): 39-49.
23. Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001; 85: 266-72.
24. 3]-octreotide: The Rotterdam experience with more than 1, 000 patients. Eur J Nucl Med 1993; 20: 716-31.
25. Lamberts SWJ. The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-82.
26. Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin-14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies. Proc Natl Acad Sci USA 2000. 97: 829-34.
27. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997; 89: 1803-9.
28. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 2000; 60: 2996-3001.
29. Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, et al. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer 2001; 92: 1168-76.
30. Kiaris H., Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G. Regression of U-87MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 2000; 6: 709-17.
31. Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, et al. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer. Clin Cancer Res 2001; 7: 2854-61.
32. Nagy A, Armatis P, Schally AV. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1, 000 times more potent: Structure-activity relationship of dunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 1996; 93: 2464-9.
33. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003; 72: 2305-20.
34. Lamberts SWJ, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metabol 2002; 13: 451-7.
35. Reubi J-C, Waser B, Schaer J-C, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995; 80: 2806-14.
36. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000; 85: 2564-71.
37. 1]-octreotide scintigraphy. Cancer Res 1995; 55(suppl): 5805s-10s.
38. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 1998; 58: 4132-7.
39. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999; 59: 1947-53.
40. Plonowski A, Schally AV, Nagy A, Sun B, Halmos G. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol 2002; 20: 397-402.
41. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J Urol 2004; 171: 911-5.
42. Reubi J.C, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992; 52: 6074-8.
43. Kahan Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, et al. Inhibition of growth of MX- 1, MCF-7, MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 1999; 82: 592-8.
44. 3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res 1999; 5: 1025-33.
45. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy 2001; 47(suppl2): 78-108.
46. Denzler B, Reubi J-C. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999; 85: 188-98.
47. Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer 2001; 37: 620-8.
48. Szereday Z, Schally AV, Szepeshazi K, Bajo A-M, Hebert F, Halmos G, et al. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 2003; 22: 1141-6.
49. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56:1823-7.
50. Fisher WE, Doran TA, Muscarella II P, Boros LG, Ellison CE, Schirmer WJ. Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst 1998; 90: 322-4.
51. Burch PA, Block M, Schroeder G, Kugler JW, Sargent DJ, Braich TA, et al. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A North Central Cancer Treatment Group study. Clin Cancer Res 2000; 6: 3486-92.
52. Raderer M, Pangerl T, Leimer M, Valencak J, Kurtaran A, Hamilton G, et al. Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. J Natl Cancer Inst 1998; 90: 1666-8.
53. Radulovic S, Nagy A, Szoke B, Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreaticcancer xenografts in nude mice. Cancer Lett 1992; 62: 263-71.
54. Benali N, Cordelier P, Calise D, Pagès P, Rochaix P, Nagy A, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000; 97: 9180-5.
55. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B, et al. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res 2002; 62: 781-8.
56. Miller GV, Farmery SM, Woodhouse LF, Primrose JN. Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br J Cancer 1992; 66: 391-5.
57. Halmos G, Sun B, Schally AV, Hebert F, Nagy A. Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab 2000; 85: 3509-12.
58. Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, et al. Antitumor effects of the cytotoxic LHRH analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002; 187: 528-37.
59. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsässer HP, et al. Receptor mediated antiproliferative effects of the cytotoxic LH-RH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000; 17: 1063-9.
60. Wang X, Krebs LJ, Al-Nuri M, Pudavar HE, Ghosal S, Liebow C, et al. A chemically labeled cytotoxic agent. Two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc Natl Acad Sci USA 1999; 96: 11081-4.
61. Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, et al. Regulation of targeted chemotherapy with cytotoxic LH-RH analog by epidermal growth factor. Cancer Res. 2000; 60: 4194-4199.
62. Arencibia JM, Schally AV, Halmos G, Nagy A, Kiaris H. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancers as demonstrated by microsatellite analyses. Anti-Cancer Drugs 2001; 12: 71-78.
63. Danila D, Schally AV, Nagy A, Alexander JM. Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1999; 96: 669-73.
64. Fernandez A-M, Van Derpoorten K, Dasnois L, Lebtahi K, Dubois, V, Lobl TJ et al. N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: An extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J Med Chem 2001; 44: 3750-3.
65. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003; 9: 4505-13.
66. Bajo AM, Schally AV, Halmos G, Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003; 9: 3742-8.
67. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324: 843-5.
68. Kovacs M, Schally AV, Nagy A, Koppan M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997; 94: 1420-5.
69. Moretti RM, Montagnani Marelli M, van Groeningen JC, Limonta P. Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 2002; 87: 3791-7.
70. Pati D, Habibi HR. Inhibition of human hepatocarcinoma cell proliferation by mammalian and fish gonadotropin-releasing hormones. Endocrinology 1995; 136: 75-84.
71. Sion-Vardi N, Kaneti J, Segal-Abramson T, Giat J, Levy J, Sharoni Y. Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol 1992; 148: 1568-70.
72. Krebs LJ, Wang X, Nagy A, Schally AV, Prasad PN, Liebow C. A conjugate of doxorubicin and an analog of luteinizing hormone-releasing hormone shows increased efficacy against oral and laryngeal cancers. Oral Oncol 2002; 38: 657-63.
73. Arencibia JM, Schally AV, Krupa M, Bajo AM, Nagy A, Szepeshazi K, et al. Targeting doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol 2001; 19: 571-7.
74. Emons G, Pahwa GS, Brack C, Sturm R, Oberhauser F, Knuppen M. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Oncol 1989; 25: 215-21.
75. 6]luteinizing hormone-releasing hormone and epithelial growth factor in human ovarian cancer. Int J Oncol 1998; 16: 489-98.
76. Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol 1999; 180: 1095-103.
77. Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti-Cancer Drugs 2002; 13: 949-56.
78. 6]luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990; 50: 1841-6.
79. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137-47.
80. Baumann KH, Kiesel L, Kaufmann M, Bastert G, Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993; 25: 37-46.
81. Halmos G, Nagy A, Lamharzi N, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 1999; 136: 129-36.
82. Szepeshazi K, Schally AV, Nagy A, Halmos G, Groot K. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancer in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs 1997; 8: 974-87.
83. Szepeshazi K, Schally AV, Nagy A. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs. Breast Cancer Res Treat 1999; 56: 267-76.
84. Kahan Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer 1999; 85: 2608-15.
85. Kahán Zs, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 2000; 59: 255-62.
86. Chatzistamou I, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G. Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Clinl Cancer Res 2000; 6: 4158-65.
87. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J, The effects of gonadotropin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990; 62: 96-9.
88. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000; 163: 623-9.
89. Tieva A, Stattin P, Wikström P, Bergh A, Damber J-E. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001; 47: 276-84.
90. Straub B, Müller M, Krause H, Schrader M, Goessl C, Heicappell R, et al. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001; 7: 2340-3.
91. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-65.
92. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan G, et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997; 10: 877-84.
93. Koppan M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999; 38: 151-8.
94. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, et al. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 2002; 176: 57-63.
95. 4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999; 83: 657-63.
96. Kiaris H, Schally AV, Nagy A, Armatis P. Targeting of cytotoxic bombesin analog AN-215 to H-69 small cell lung carcinoma as demonstrated by semi-quantitative microsatellite analysis in vitro. Tumor Targeting 2000; 4: 266-70.
97. Orosz A, Schrett J, Nagy J, Bartha L, Schon I, Nyeki O. New short-chain analogs of a substance P antagonist inhibit proliferation of human small cell lung cancer cells in vitro and in vivo. Int J Cancer 1995; 60: 82-7.
98. Yegen BC. Bombesin-like peptides: candidiates as diagnostic and therapeutic tools. Curr Pharm Design 2003; 9: 1013-22.
99. Sun B, Schally AV, Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Peptides 2000; 90: 77-84.
100. Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J Med Chem 1999; 42: 4919-24.
101. Markwalder R, Reubi J-C. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159.
102. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for 3 receptor subtypes in human prostate cancers. Prostate 2000; 42: 295-303.
103. 4)bombesin by tumor cells. Prostate 1994; 25: 29-38.
104. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, et al. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 1985; 316: 823-6.
105. Moody TW, Mahmoud S, Staley J, Naldini L, Cirillo D, South V, et al. Human glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin releasing peptide. J Mol Neurosci 1989; 1: 235-42.
106. McCann SM, Haens G, Mastronardi C, Walczewska A, Karanth S, Rettori V, et al. The role of nitric oxide (NO) in control of LHRH release that mediates gonadotropin release and sexual behavior. Curr Pharm Design 2003; 9(5): 381-90.
107. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Design 2003; 9(6): 495-509.
108. Yegen BC. Bombesin-like peptides: candidates as diagnostic and therapeutic tools. Curr Pharm Design 2003; 9(12): 1013-22.